StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.80+0.10 (+0.60%)

Close on Nov 17, 2026Market cap $3.06BP/E –Yield –

Xeris Biopharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Xeris Biopharma's ebitda for the twelve months ending Jun 30, 2026 was $37.93M. For fiscal 2025 it was $26.21M. The highest annual figure on record is $26.21M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$26.21M–
FY2024Dec 31, 2024-$32.42M–
FY2023Dec 31, 2023-$42.52M–
FY2022Dec 31, 2022-$80.54M–
FY2021Dec 31, 2021-$113.83M–
FY2020Dec 31, 2020-$82.08M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.50M+14.3%
Q1 FY2026Mar 31, 2026$8.25M–
Q4 FY2025Dec 31, 2025$17.11M+758.8%
Q3 FY2025Sep 30, 2025$7.07M–
Q2 FY2025Jun 30, 2025$4.81M–
Q1 FY2025Mar 31, 2025-$2.78M–
Q4 FY2024Dec 31, 2024$1.99M–
Q3 FY2024Sep 30, 2024-$12.59M–
Q2 FY2024Jun 30, 2024-$7.91M–
Q1 FY2024Mar 31, 2024-$13.92M–
Q4 FY2023Dec 31, 2023-$9.50M–
Q3 FY2023Sep 30, 2023-$4.52M–
Q2 FY2023Jun 30, 2023-$15.59M–
Q1 FY2023Mar 31, 2023-$12.91M–
Q4 FY2022Dec 31, 2022-$14.80M–
Q3 FY2022Sep 30, 2022-$18.42M–
Q2 FY2022Jun 30, 2022-$18.56M–
Q1 FY2022Mar 31, 2022-$28.75M–
Q4 FY2021Dec 31, 2021-$47.92M–
Q3 FY2021Sep 30, 2021-$24.04M–
Q2 FY2021Jun 30, 2021-$25.47M–
Q1 FY2021Mar 31, 2021-$16.40M–
Q4 FY2020Dec 31, 2020-$18.90M–

More Xeris Biopharma figures

See a number that looks wrong?